Intellect Neurosciences, Inc. (ILNS.OB) Receives Key Patents Related to Ongoing Alzheimer’s Solutions
Intellect Neurosciences, www.intellectns.com – the biopharma company developing a variety of disease-modifying therapeutics for Alzheimer’s disease (AD) and other disorders, reported reception of a patent from the United States Patent and Trademark Office today for the Company’s internal AD monoclonal antibody program. The Company is quickly establishing a sophisticated platform for addressing AD which can boast improved efficacy and safety over any competitors. Chairman and CEO of ILNS, Dr. Daniel Chain, Ph.D., inventor of the ANTISENILIN® monoclonal antibody platform designed to prevent/treat AD noted the importance of this patent as it covers two highly specific monoclonal antibodies (acquired from Immuno-Biological…